In yesterday’s Wall Street session, Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) shares traded at $0.68, up 12.77% from the previous session.
3 analysts cover Aeglea BioTherapeutics Inc. (NASDAQ:AGLE), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $0.35, we find $3.18. Given the previous closing price of $0.60, this indicates a potential upside of 430.0 percent. AGLE stock price is now 167.07% away from the 50-day moving average and 48.91% away from the 200-day moving average. The market capitalization of the company currently stands at $51.44M.
The stock has received a hold rating from 2 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $3.18 as their price target over the next twelve months.
With the price target of $12, Piper Sandler recently initiated with Overweight rating for Aeglea BioTherapeutics Inc. (NASDAQ: AGLE).
In other news, Souza Marcio, Director bought 90,000 shares of the company’s stock on Aug 25. The stock was bought for $50,472 at an average price of $0.56. Upon completion of the transaction, the Director now directly owns 90,000 shares in the company, valued at $61200.0. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AGLE stock. A new stake in Aeglea BioTherapeutics Inc. shares was purchased by CARLYLE GROUP INC. during the first quarter worth $163,000. JANE STREET GROUP, LLC invested $29,000 in shares of AGLE during the first quarter. In the first quarter, VIRTU FINANCIAL LLC acquired a new stake in Aeglea BioTherapeutics Inc. valued at approximately $13,000. In total, there are 71 active investors with 78.80% ownership of the company’s stock.
On Tuesday morning Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) stock kicked off with the opening price of $0.6014. During the past 12 months, Aeglea BioTherapeutics Inc. has had a low of $0.11 and a high of $1.56. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.50, and a quick ratio of 3.50. The fifty day moving average price for AGLE is $0.2637 and a two-hundred day moving average price translates $0.4554 for the stock.
The latest earnings results from Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.2, missing analysts’ expectations of -$0.18 by -0.02. This compares to -$0.37 EPS in the same period last year. The company reported revenue of $0.2 million for the quarter, compared to $1.36 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -85.46 percent. For the current quarter, analysts expect AGLE to generate $200k in revenue.
Aeglea BioTherapeutics Inc.(AGLE) Company Profile
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company’s therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
